Autologous hematopoietic cell transplantation in multiple sclerosis

References

• Mackenzie IS, Morant SV, Bloomfield GA, et al. Incidence and prevalence of multiple sclerosis in the UK 1990–2010: a descriptive study in the general practice research database. J Neurol Neurosurg Psychiatry. 2014;85(1):76–84. DOI:10.1136/jnnp-2013-305450
   PubMed Web of Science ®Google Scholar
• Leary S, Giovannoni G, Howard R, et al. Multiple sclerosis and demyelinating diseases. In: Clarke C, Howard R, Rossor M, Shorvon S, editors. Neurology a queen square textbook. West Sussex: John Wiley & Sons Ltd.; 2009. p. 411–449.
   Google Scholar
• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–286. DOI:10.1212/WNL.0000000000000560
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (Edss). Neurology. 1983;33(11):1444–1452.
   PubMed Web of Science ®Google Scholar
• Snowden JA, Patton WN, O’Donnell JL, et al. Prolonged remission of longstanding systemic lupus erythematosus after autologous bone marrow transplant for non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1997;19(12):1247–1250. DOI:10.1038/sj.bmt.1700815
   PubMed Web of Science ®Google Scholar
• McAllister LD, Beatty PG, Rose J. Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis. Bone Marrow Transplant. 1997;19(4):395–397. DOI:10.1038/sj.bmt.1700666
   PubMed Web of Science ®Google Scholar
• van Gelder M, van Bekkum DW. Treatment of relapsing experimental autoimmune encephalomyelitis in rats with allogeneic bone marrow transplantation from a resistant strain. Bone Marrow Transplant. 1995;16(3):343–351.
   PubMed Web of Science ®Google Scholar
• Fassas A, Anagnostopoulos A, Kazis A, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant. 1997;20(8):631–638. DOI:10.1038/sj.bmt.1700944
   PubMed Web of Science ®Google Scholar
• Snowden JA. Rebooting autoimmunity with autologous HSCT. Blood. 2016;127(1):8–10. DOI:10.1182/blood-2015-11-678607
   PubMed Web of Science ®Google Scholar
• Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood. 2003;102(7):2364–2372. DOI:10.1182/blood-2002-12-3908
   PubMed Web of Science ®Google Scholar
• Fassas A, Passweg JR, Anagnostopoulos A, et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurology. 2002;249(8):1088–1097. DOI:10.1007/s00415-002-0800-7 .
   PubMed Web of Science ®Google Scholar
• Samijn JPA, te Boekhorst PAW, Mondria T, et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006;77(1):46–50. DOI:10.1136/jnnp.2005.063883
   PubMed Web of Science ®Google Scholar
• Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009;8(3):244–253. DOI:10.1016/S1474-4422(09)70017-1
   PubMed Web of Science ®Google Scholar
• Openshaw H, Lund BT, Kashyap A, et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant. 2000;6(5a):563–575.
   PubMed Web of Science ®Google Scholar
• Burt RK, Traynor AE, Pope R, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood. 1998;92(10):3505–3514.
   PubMed Web of Science ®Google Scholar
• Saccardi R, Kozak T, Bocelli-Tyndall C, et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European group for blood and marrow transplantation autoimmune diseases working party database. Mult Scler. 2006;12(6):814–823.
   PubMed Web of Science ®Google Scholar
• Burt RK, Cohen BA, Russell E, et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood. 2003;102(7):2373–2378. DOI:10.1182/blood-2003-03-0877
   PubMed Web of Science ®Google Scholar
• Reston JT, Uhl S, Treadwell JR, et al. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. Mult Scler. 2011;17(2):204–213. DOI:10.1177/1352458510383609
   PubMed Web of Science ®Google Scholar
• Snowden JA, Saccardi R, Allez M, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the european group for blood and marrow transplantation. Bone Marrow Transplant. 2012;47(6):770–790. DOI:10.1038/bmt.2011.185
   PubMed Web of Science ®Google Scholar
• Curro D, Vuolo L, Gualandi F, et al. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: a MRI-based clinical study. Mult Scler. 2015;21(11):1423–1430. DOI:10.1177/1352458514564484
   PubMed Web of Science ®Google Scholar
• Atkins HL, Bowman M, Allan D, et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet. Published Online June 9, 2016. DOI:10.1016/S0140-6736(16)30169-6 .
   Web of Science ®Google Scholar
• Darlington PJ, Touil T, Doucet JS, et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol. 2013;73(3):341–354. DOI:10.1002/ana.23784
   PubMed Web of Science ®Google Scholar
• Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol. 2015;72(2):159–169. DOI:10.1001/jamaneurol.2014.3780 .
   PubMed Web of Science ®Google Scholar
• Abrahamsson SV, Angelini DF, Dubinsky AN, et al. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain. 2013;136(Pt 9):2888–2903. DOI:10.1093/brain/awt182
   PubMed Web of Science ®Google Scholar
• Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med. 2005;201(5):805–816. DOI:10.1084/jem.20041679
   PubMed Web of Science ®Google Scholar
• Berzins SP, Uldrich AP, Sutherland JS, et al. Thymic regeneration: teaching an old immune system new tricks. Trends Mol Med. 2002;8(10):469–476.
   PubMed Web of Science ®Google Scholar
• Hug A, Korporal M, Schroder I, et al. Thymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosis. J Immunol. 2003;171(1):432–437.
   PubMed Web of Science ®Google Scholar
• Muraro PA, Robins H, Malhotra S, et al. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest. 2014;124(3):1168–1172. DOI:10.1172/JCI71691 .
   PubMed Web of Science ®Google Scholar
• Burman J, Iacobaeus E, Svenningsson A, et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry. 2014;85(10):1116–1121. DOI:10.1136/jnnp-2013-307207 .
   PubMed Web of Science ®Google Scholar
• Burt RK, Balabanov R, Han X, et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2015;313(3):275–284. DOI:10.1001/jama.2014.17986 .
   PubMed Web of Science ®Google Scholar
• Shevchenko YL, Novik AA, Kuznetsov AN, et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol. 2008;36(8):922–928.
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910. DOI:10.1056/NEJMoa044397
   PubMed Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (London, England). 2012;380(9856):1819–1828. DOI:10.1016/S0140-6736(12)61769-3
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (London, England). 2012;380(9856):1829–1839. DOI:10.1016/S0140-6736(12)61768-1
   PubMed Web of Science ®Google Scholar
• Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012;78(14):1069–1078. DOI:10.1212/WNL.0b013e31824e8ee7
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401.
   PubMed Web of Science ®Google Scholar
• Sormani MP, Muraro PA, Saccardi R, et al. NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs. Mult Scler. 2016. DOI:10.1177/1352458516645670
   Google Scholar
• Yong VW, Chabot S, Stuve O, et al. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology. 1998;51(3):682–689.
   PubMed Web of Science ®Google Scholar
• Ebers, GC, et al. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Prisms (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis) study group. Lancet. 1998;352(9139):1498–1504.
   PubMed Web of Science ®Google Scholar
• Weber MS, Hohlfeld R, Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics. 2007;4(4):647–653. DOI:10.1016/j.nurt.2007.08.002
   PubMed Web of Science ®Google Scholar
• La Mantia L, Di Pietrantonj C, Rovaris M, et al. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2014;7:CD009333.
   Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911–923. DOI:10.1056/NEJMoa044396
   PubMed Web of Science ®Google Scholar
• Butzkueven H, Kappos L, Pellegrini F, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry. 2014;85(11):1190–1197. DOI:10.1136/jnnp-2013-306936
   PubMed Web of Science ®Google Scholar
• Planas R, Martin R, Sospedra M. Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life. Patient Relat Outcome Meas. 2014;5:25–33. DOI:10.2147/PROM.S41768
   PubMedGoogle Scholar
• Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870–1880. DOI:10.1056/NEJMoa1107829
   PubMed Web of Science ®Google Scholar
• Martinelli Boneschi F, Rovaris M, Capra R, et al. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2005;(4):Cd002127.
   Google Scholar
• Mancardi GL, Sormani MP, Gualandi F, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology. 2015;84(10):981–988. DOI:10.1212/WNL.0000000000001329
   PubMed Web of Science ®Google Scholar
• Cohen JA. Mesenchymal stem cell transplantation in multiple sclerosis. J Neurol Sci. 2013;333(1–2):43–49. DOI:10.1016/j.jns.2012.12.009
   PubMed Web of Science ®Google Scholar
• Hinterberger W, Hinterberger-Fischer M, Marmont A. Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcome after stem cell transplantation in human autoimmune diseases. Bone Marrow Transplant. 2002;30(11):753–759. DOI:10.1038/sj.bmt.1703686
   PubMed Web of Science ®Google Scholar
• Krasulova E, Trneny M, Kozak T, et al. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult Scler. 2010;16(6):685–693. DOI:10.1177/1352458510364538
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Brara SM, Beaber BE, et al. Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology. 2013;80(19):1734–1739. DOI:10.1212/WNL.0b013e3182918cc2
   PubMed Web of Science ®Google Scholar
• Ni XS, Ouyang J, Zhu WH, et al. Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin Transplant. 2006;20(4):485–489. DOI:10.1111/j.1399-0012.2006.00510.x
   PubMed Web of Science ®Google Scholar
• Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol. 2008;7(7):626–636. DOI:10.1016/S1474-4422(08)70138-8
   PubMed Web of Science ®Google Scholar
• Atkins HL, Freedman MS. Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned. Neurotherapeutics. 2013;10.1:68–76. DOI:10.1007/s13311-012-0162-5
   Web of Science ®Google Scholar
• Morris ES, Sharrack B, Dalley CD, et al. The Uhthoff phenomenon: a potential post transplant complication in advanced progressive multiple sclerosis. Bone Marrow Transplant. 2007;40(10):1003–1004. DOI:10.1038/sj.bmt.1705854
   PubMed Web of Science ®Google Scholar
• Bhatia S. Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. Expert Rev Hematol. 2011;4(4):437–454. DOI:10.1586/ehm.11.39
   PubMed Web of Science ®Google Scholar
• Johnson MD, Lavin P, Whetsell WO Jr. Fulminant monophasic multiple sclerosis, Marburg’s type. J Neurol Neurosurg Psychiatry. 1990;53(10):918–921.
   PubMed Web of Science ®Google Scholar
• Tappenden P, Saccardi R, Confavreux C, et al. Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis. Bone Marrow Transplant. 2010;45(6):1014–1021. DOI:10.1038/bmt.2009.305
   PubMed Web of Science ®Google Scholar